Alignment Healthcare, Inc. disclosed that Dawn Christine Maroney, the company's President and Officer, executed a series of stock transactions on July 15, 2026, involving both the acquisition and disposition of common shares. The transactions, conducted under a Rule 10b5-1 pre-arranged trading plan adopted in March 2026, resulted in a net reduction in Maroney's direct beneficial ownership of the healthcare company's stock. Investors monitoring insider trading activity may view such pre-planned transactions as an indicator of structured capital management by company leadership.
Key Points
- NASDAQ: ALHC
- President Dawn Maroney acquired 152,068 shares and sold 177,068 shares on July 15, 2026
- Acquisition price was $9.06 per share; sale prices ranged from $20.29 to $21.14 per share with a weighted-average of $20.8281
- All transactions were executed under a Rule 10b5-1 trading plan adopted on March 13, 2026, which allows pre-arranged securities transactions to satisfy affirmative defense conditions under insider trading regulations
- Following the transactions, Maroney's direct beneficial ownership decreased to 922,313 shares of common stock
Overview of President Maroney's Trading Activity
The disclosure document filed on July 16, 2026, details the stock transactions executed by Dawn Christine Maroney, who holds the position of President at Alignment Healthcare, Inc. On July 15, 2026, Maroney engaged in two distinct transactions involving the company's common stock. The first transaction involved the acquisition of 152,068 shares at $9.06 per share, while the second transaction resulted in the disposition of 177,068 shares at prices ranging from $20.29 to $21.14 per share. These transactions resulted in a net reduction in the number of shares directly owned by Maroney, reflecting a structured approach to her equity position in the healthcare company.
The magnitude of these transactions represents a meaningful adjustment to Maroney's shareholding. The acquisition of over 152,000 shares and the simultaneous sale of approximately 177,000 shares demonstrate significant portfolio activity during a single trading date. The difference in acquisition and sale prices—with shares being purchased at $9.06 and sold at substantially higher prices—suggests that these transactions may reflect different grant dates or exercise prices associated with Maroney's compensation arrangements or equity incentive programs at the company.
Rule 10b5-1 Trading Plan Framework
The disclosure explicitly states that both transactions were executed pursuant to a Rule 10b5-1 pre-arranged trading plan adopted on March 13, 2026. Rule 10b5-1 plans are contractual arrangements that allow company insiders to establish written instructions for the purchase or sale of securities according to predetermined terms. These plans are designed to satisfy the affirmative defense conditions of SEC Rule 10b5-1(c), which permits insiders to trade securities while avoiding certain insider trading restrictions, provided they adopt the plan when they do not possess material nonpublic information and comply with the plan's terms.
By utilizing a Rule 10b5-1 plan, company insiders can demonstrate that their trading decisions were made independently of any knowledge of material nonpublic information. The adoption of such a plan by Maroney approximately four months prior to the July 2026 transactions suggests that the trades were predetermined in nature and not responsive to any company developments announced near the transaction date. This regulatory framework provides transparency to the market regarding insider trading activity and offers legal protection to executives who wish to manage their equity positions in a systematic manner.
Share Acquisition Details and Pricing
The filing indicates that Maroney acquired 152,068 shares of Alignment Healthcare common stock at $9.06 per share. The transaction code designation as "M" in the disclosure document refers to a grant or other acquisition that is not a purchase or sale. This categorization suggests that the shares acquired may have resulted from the exercise of stock options or the vesting of restricted stock units granted as part of Maroney's compensation package. Following this acquisition, Maroney's total direct beneficial ownership increased to 1,099,381 shares immediately after the acquisition transaction was recorded.
The $9.06 acquisition price aligns with typical exercise prices for stock options granted to company executives. The filing provides additional context by noting that options with an exercise price of $9.06 vested 25 percent on each of the first four anniversaries of the grant date of March 8, 2022. This information indicates that the July 2026 acquisition likely represented the exercise of vested options that had been granted nearly four years earlier. The structured vesting schedule demonstrates the long-term incentive nature of the equity grants provided to company leadership.
Share Disposition and Weighted-Average Sale Price
Maroney sold 177,068 shares of Alignment Healthcare common stock on the same date, July 15, 2026. The filing reports a weighted-average sale price of $20.8281 per share, with individual share prices within the transaction ranging from $20.29 to $21.14. The reporting person, through her attorney-in-fact Christopher J. Joyce, undertook to provide detailed information regarding the number of shares sold at each specific price within the range upon request. This transparency measure ensures that the SEC, the company, and shareholders can obtain complete details about the pricing of the shares sold.
The significant spread between the acquisition price of $9.06 and the sale prices ranging from $20.29 to $21.14 represents a substantial appreciation in the underlying stock value. The decision to sell shares at these price levels may reflect portfolio rebalancing objectives or personal financial planning decisions by Maroney. The sale transaction reduced her direct beneficial ownership to 922,313 shares, representing a net decrease of 177,000 shares from the combined position following the acquisition transaction.
Net Impact on Beneficial Ownership Position
The combined effect of the acquisition and disposition transactions resulted in a net reduction in Maroney's direct beneficial ownership of Alignment Healthcare common stock. The filing demonstrates that after acquiring 152,068 shares, which temporarily increased her holdings to 1,099,381 shares, the subsequent sale of 177,068 shares brought her final direct beneficial ownership to 922,313 shares. This represents a net decrease of 24,913 shares compared to her beneficial ownership prior to the two transactions on July 15, 2026.
The reduction in Maroney's direct ownership stake, while still maintaining substantial holdings of over 922,000 shares, may reflect various business and personal considerations. Significant insider stock sales are often monitored by market participants and analysts seeking signals about management's confidence in the company's valuation or their liquidity needs. However, the execution of these transactions pursuant to a pre-arranged Rule 10b5-1 plan established nearly four months earlier suggests that the timing and structure were determined well in advance rather than in response to any specific recent developments at the company.
Executive Compensation Structure and Option Vesting
The filing provides relevant details about Maroney's equity compensation arrangements at Alignment Healthcare. The options exercised during the acquisition portion of the July 15 transaction had an exercise price of $9.06 and were granted on March 8, 2022. According to the filing, these options vested 25 percent on each of the first four anniversaries of the grant date, subject to Maroney's continued service to the company. This graduated vesting schedule is a standard feature of executive equity compensation, designed to encourage employee retention and align the interests of management with long-term company performance.
The exercise and subsequent sale of vested options represents a common practice among company executives seeking to monetize their equity compensation while managing their portfolio exposure to company stock. By exercising options at the $9.06 strike price and immediately selling shares at significantly higher market prices, Maroney realized gains reflecting the appreciation of Alignment Healthcare stock since the option grant date. The execution of these transactions through a pre-arranged Rule 10b5-1 plan provides a mechanism for executives to regularly and systematically manage their equity positions in accordance with predetermined trading schedules.
Regulatory Compliance and Insider Trading Safeguards
The filing demonstrates compliance with SEC Form 4 reporting requirements, which mandate that company officers and directors report changes in their beneficial ownership of company securities. The disclosure was filed on July 16, 2026, one business day after the transactions occurred, consistent with the regulatory timeline for Form 4 filings. The checkbox notation indicating that the transactions were made pursuant to a Rule 10b5-1 trading plan provides explicit disclosure to the market regarding the regulatory framework governing the insider trading activity.
The use of an attorney-in-fact, Christopher J. Joyce, to sign the disclosure on behalf of Maroney is a common administrative practice that does not diminish the accuracy or legal effect of the filing. The attestation language on Form 4 includes warnings that intentional misstatements or omissions of facts constitute federal criminal violations under 18 U.S.C. Section 1001 and 15 U.S.C. Section 78ff(a), underscoring the serious legal consequences associated with inaccurate insider trading disclosures. These safeguards aim to ensure the integrity and accuracy of beneficial ownership information provided to the investing public.
Context for Investor Monitoring and Market Implications
Investors and market analysts tracking insider trading activity at Alignment Healthcare may find Maroney's transactions noteworthy for several reasons. The execution of transactions under a pre-arranged trading plan indicates that the decisions regarding the timing, quantity, and prices associated with the trades were made months in advance, reducing the likelihood that the trading activity was responsive to material nonpublic information. The sale of shares at prices exceeding $20 per share while repurchasing shares through option exercise at $9.06 per share represents a substantial financial transaction by the company's President.
The magnitude of trading activity by a senior executive can be interpreted in various ways by different market participants. Some investors may view the sale of shares as a signal of the executive's intention to diversify holdings or address personal financial needs, while others may focus on the fact that the transactions were pre-planned and do not necessarily reflect any recent assessment of company prospects. The disclosed information allows investors to form their own conclusions about the significance of the insider trading activity while maintaining confidence that the transactions were executed in compliance with applicable securities laws and regulations.
Administrative and Technical Aspects of the Filing
The Form 4 filing provides several administrative details relevant to understanding the complete transaction record. The earliest transaction date listed in the filing is July 15, 2026, with the filing itself submitted to the SEC on July 16, 2026. The filing indicates that it was submitted by one reporting person, Dawn C. Maroney, and includes both Table I entries for non-derivative securities (common stock) and Table II entries for derivative securities (stock options). The document's structure and content follow established SEC format requirements designed to ensure consistent and comparable disclosure of insider trading activity across all public companies.
The filing also notes the estimated average burden of 0.5 hours per response for completing Form 4, reflecting the SEC's assessment of the administrative effort required to prepare and file such disclosures. The OMB approval number 3235-0287 indicates that the form's information collection requirements have been approved by the Office of Management and Budget under the Paperwork Reduction Act. These procedural elements underscore the regulatory framework within which Alignment Healthcare and its insiders operate when reporting changes in beneficial ownership of company securities.



Please wait processing your request...